Bioray Biotech Co (ROCO:7561) Other Current Liabilities: NT$14.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7561 Bioray Biotech Co Ltd ROCO:7561
81 GF Score
Price NT$17.10
GF Value NT$29.57
Valuation Significantly Undervalued
View Full Analysis

What is Bioray Biotech Co Other Current Liabilities?

Bioray Biotech Co ROCO:7561 +0.87% 81 Other Current Liabilities is NT$14.1 Mil as of Dec. 2025. GuruFocus rates ROCO:7561 with a GF Score™ of 81/100 and a GF Value™ of NT$29.57 (Significantly Undervalued).

Bioray Biotech Co's other current liabilities for the quarter that ended in Dec. 2025 was NT$14.1 Mil.

Bioray Biotech Co's quarterly other current liabilities declined from Dec. 2024 (NT$20.5 Mil) to Jun. 2025 (NT$12.7 Mil) but then increased from Jun. 2025 (NT$12.7 Mil) to Dec. 2025 (NT$14.1 Mil).

Bioray Biotech Co's annual other current liabilities increased from Dec. 2023 (NT$14.6 Mil) to Dec. 2024 (NT$20.5 Mil) but then declined from Dec. 2024 (NT$20.5 Mil) to Dec. 2025 (NT$14.1 Mil).

Bioray Biotech Co Other Current Liabilities Related Terms

Bioray Biotech Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Bioray Biotech Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioray Biotech Co Other Current Liabilities Chart

Bioray Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only 20.06 17.91 14.62 20.47 14.09

Bioray Biotech Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.62 13.66 20.47 12.70 14.09
ROCO:7561
81GF Score
Bioray Biotech Co Ltd ROCO:7561
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioray Biotech Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of NT$14.1 Mil mean?
Bioray Biotech Co (ROCO:7561) has a Other Current Liabilities of NT$14.1 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bioray Biotech Co.
Is Bioray Biotech Co's Other Current Liabilities too high?
Bioray Biotech Co's current Other Current Liabilities is NT$14.1 Mil. Overall, Bioray Biotech Co has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's Other Current Liabilities compare to ZTS?
Bioray Biotech Co's Other Current Liabilities of NT$14.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Bioray Biotech Co. Bioray Biotech Co's current Other Current Liabilities is NT$14.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$29.57, compared to a current price of NT$17.10 — trading 42.2% below its estimated fair value. The current Other Current Liabilities is NT$14.1 Mil. Bioray Biotech Co's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current Other Current Liabilities is NT$14.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?

Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued. The current stock price of NT$17.10 is trading 42.2% below its estimated GF Value™ of NT$29.57. GuruFocus considers Bioray Biotech Co to be Significantly Undervalued.

Key valuation signals for ROCO:7561:

  • Other Current Liabilities: NT$14.1 Mil
  • GF Value™: NT$29.57 vs. price of NT$17.10 (42.2% below fair value)
  • GF Score™: 81/100

No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioray Biotech Co Business Description

Address No. 1, Dali 2nd Road, Southern Science Park, Shanhua District, Tainan, TWN, 90846
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
81GF Score

Get the complete analysis for ROCO:7561

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.10
Price
NT$29.57
GF Value